Treatment of Poorly Differentiated Neuroendocrine Carcinoma of the Pancreas

  • Anumeha Gupta Tufts University School of Medicine. Boston, MA, USA
  • Marvin Duque Tufts University School of Medicine. Boston, MA, USA
  • Muhammad Wasif Saif Tufts University School of Medicine. Boston, MA, USA
Keywords: Carcinoma, Neuroendocrine, Digestive System Neoplasms, Drug Therapy, Etoposide, everolimus

Abstract

Poorly differentiated neuroendocrine carcinoma is a rare malignancy that remains a challenge to treat. Poorly differentiated neuroendocrine carcinoma occurs at an incidence of 2% annually in United States. The current standard of care is based largely upon retrospective data. There remains a need for large prospective cooperative group trials in the management of poorly differentiated neuroendocrine carcinoma. In this paper, we will review abstract #e15096 (Paclitaxel, carboplatin, and etoposide (TCE) in advanced poorly differentiated neuroendocrine carcinoma) by Loeffler et al. and #e15071 (Poorly differentiated neuroendocrine carcinoma (NEC G3): prognostic factors and potential novel targets) by Heetfeld et al. presented at the 2013 ASCO Annual Meeting highlighting treatment options in first and second lines for poorly differentiated neuroendocrine carcinoma.

Image: Main gate, Tufts University. Medford, MA, USA. (Author: Daderot; Wikimedia Commons)

Downloads

Download data is not yet available.

Author Biography

Anumeha Gupta, Tufts University School of Medicine. Boston, MA, USA
second year fellow in the department of hematology/oncology at Tufts medical center, Boston MA USA

References

Brenner B, Tang LH, Klimstra DS, et al: Small cell carcinomas of the gastrointestinal tract: A review. J Clin Oncol 22:2730-2739, 2004

Van der Gaast A, Verwey J, Prins E, et al: Chemotherapy as treatment of choice in extrapulmonary undifferentiated small cell carcinomas. Cancer 65:422-424, 1990

Yalan S, Ozsik Y, Tekuzman G: Metastatic small-cell carcinoma of the rectum responding dramatically to combination chemotherapy. Am J Clin Oncol 21:75-76, 1998

Mitry E, Baudin E, Ducreux M, et al: Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81:1351-1355, 1999

Fjallskog M, Granberg D, et al: Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 92:1101-1107, 2001

Hainsworth JD, Gray JR, Stroup SL, et al: Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: Comparison of sequential phase II trials using different dose intensities. J Clin Oncol 15:3464-3470,1997

Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514–23.

Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, et al.Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010;28:69–76.

Loeffler LM, Mauersberger E, Weimann A, et al. Paclitaxel, carboplatin, and etoposide (TCE) in advanced poorly differentiated neuroendocrine carcinoma. J Clin Oncol 31, 2013 (suppl; abstr #e15096)

Heetfeld M, Kasajima A, Koch A, et al. Poorly differentiated neuroendocrine carcinoma (NEC G3): Prognostic factors and potential novel targets. J Clin Oncol 31, 2013 (suppl; abstr #e15071)

Main gate, Tufts University. Medford, MA, USA
Published
2013-07-10
How to Cite
Gupta, A., Duque, M., & Saif, M. (2013). Treatment of Poorly Differentiated Neuroendocrine Carcinoma of the Pancreas. JOP. Journal of the Pancreas, 14(4), 381-383. https://doi.org/10.6092/1590-8577/1661
Section
Highlights from the “2013 ASCO Annual Meeting”. Chicago, IL, USA. May 31 - June 4, 2013

Most read articles by the same author(s)

1 2 > >>